Oncolytic adenovirus treatment induces the reduction of tumor dimension in a model of mice lung adenocarcinoma multicellular spheroids

AUTORI

ABSTRACT

Introduction: immunotherapy is a type of treatment that harnesses the power of the immune system by modulating the
immune response and improving its ability to recognize and destroy cancer cells. In clinical practice, there are different
types of immunotherapies used to treat cancer, including immune checkpoint inhibitors (ICIs). ICIs work by blocking
proteins in cancer cells that prevent the immune system from recognizing and attacking them. ICIs immunotherapy could
be combined with oncolytic virotherapy to enhance the overall therapeutic effect.
Methods: in our study, we generated multicellular spheroids models of murine lung adenocarcinoma using 70 000 cells/
spheroids. We selected the multicellular spheroids model for its ability to mimic the in vivo tridimensional structure. We
then infected the multicellular spheroids with 5 000 multiplicities of infection (MOI) of two oncolytic adenoviruses, Ad5D24
and Ad5D24-anti-PD-L1-scFv. To mimic the immune system in vitro, we isolated naïve splenocytes from C57BL/6J mice
spleen and performed a co-culture assay.
Results: Infection of the murine lung adenocarcinoma spheroids with either oncolytic adenovirus induced a reduction of
the area; the highest area reduction was obtained with a combination between Ad5D24-Anti-PD-L1-scFv and splenocytes.
Conclusions: In line with the results obtained, we claim that the lung adenocarcinoma cell line is a suitable model to
generate multicellular spheroids, contributing to standardize 3D culture models, and although the in vivo environment is
more complex than in vitro, the 3D model could represent a good compromise.

BIBLIOGRAFIA

REFERENCES
1. Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res 2019;79:4557-67.
2. Laplane L, Duluc D, Bikfalvi A, Larmonier N, Pradeu T. Beyond the tumour microenvironment. Int J Cancer 2019;145:2611-8.
3. Pietras K, Östman A. Hallmarks of cancer: Interactions with the tumor stroma. Exp Cell Res 2010;316:1324-31. 45
4. Fontana F, Marzagalli M, Sommariva M, Gagliano N, Limonta P. In vitro 3D cultures to model the tumor microenvironment. Cancers (Basel) 2021;13:2970.
5. Najafi M, Goradel NH, Farhood B, Salehi E, Solhjoo S, Toolee H, et al. Tumor microenvironment: Interactions and therapy. J Cell Physiol 2019;234:5700-21.
6. Albini A, Bruno A, Noonan DM, Mortara L. Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: Implications for immunotherapy. Front Immunol. 2018;9:527.
7. Zhao P, Wang Y, Kang X, Wu A, Yin W, Tang Y, et al. Dual-targeting biomimetic delivery for anti-glioma activity: Via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy. Chem Sci. 2018;9:267489.
8. Gasser S, Lim LHK, Cheung FSG. The role of the tumour microenvironment in immunotherapy. Endocr Relat Cancer 2017;24:T283-95.
9. Coulie PG, Van Den Eynde BJ, Van Der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: At the core of cancer immunotherapy. Nat Rev Cancer [Internet]. 2014;14:135-46.
10. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-71.
11. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 2016;6:827-37.
12. Ascierto PA, Capone M, Urba WJ, Bifulco CB, Botti G, Lugli A, et al. The additional facet of immunoscore: Immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med 2013;11:8-11.
13. Mortaezaee K, Majidpoor J. Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1. Biomed Pharmacother 2023;163:114824.
14. Gromeier M. Oncolytic viruses for cancer therapy. Am J Cancer. 2003;2:313-23.
15. Tripodi L, Vitale M, Cerullo V, Pastore L. Oncolytic adenoviruses for cancer therapy. Int J Mol Sci 2021;22:1-15.
16. Bates EA, Lovatt C, Plein AR, Davies JA, Siebzehnrubl FA, Parker AL. Engineering Adenoviral Vectors with improved GBM selectivity. Viruses 2023;15:1086.
17. Vitale M, Scialò F, Passariello M, Leggiero E, D’Agostino A, Tripodi L, et al. Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv improves anti-tumoral efficacy in a melanoma mouse model. Front Oncol 2022;12:1-12.
18. Feola S, Russo S, Martins B, Lopes A, Vandermeulen G, Fluhler V, et al. Peptides-Coated oncolytic vaccines for cancer personalized medicine. Front Immunol 2022;13:1-16.
19. Liu W, Wang X, Feng X, Yu J, Liu X, Jia X, et al. Oncolytic adenovirus-mediated intratumoral expression of TRAIL and CD40L enhances immunotherapy by modulating the tumor microenvironment in immunocompetent mouse models. Cancer Lett 2022;535:215661.
20. Wang Y, Huang P, Hu Y, Guo K, Jia X, Huang B, et al. An oncolytic adenovirus delivering TSLC1 inhibits Wnt signaling pathway and tumor growth in SMMC-7721 xenograft mice model. Acta Biochim Biophys Sin (Shanghai) 2021;53:766-74.
21. Saito Y, Matsumoto N, Yamanaka S, Yokoo T, Kobayashi E. Beneficial Impact of Interspecies Chimeric Renal Organoids Against a Xenogeneic Immune Response. Front Immunol 2022;13:1-10.
22. Lin RZ, Chang HY. Recent advances in three-dimensional multicellular spheroid culture for biomedical research. Biotechnol J 2008;3:1172-84.
23. Järvinen E, Hammer HS, Pötz O, Ingelman-Sundberg M, Stage TB. 3D Spheroid primary human hepatocytes for prediction of cytochrome P450 and drug transporter induction. Clin Pharmacol Ther 2023;113:1284-94.
24. Curcio E, Salerno S, Barbieri G, De Bartolo L, Drioli E, Bader A. Mass transfer and metabolic reactions in hepatocyte spheroids cultured in rotating wall gas-permeable membrane system. Biomaterials 2007;28:5487-97.
25. Armendáriz-Borunda J, Bastidas-Ramírez BE, Sandoval-Rodríguez A, González-Cuevas J, Gómez-Meda B, García-Bañuelos J. Production of first generation adenoviral vectors for preclinical protocols: amplification, purification and functional titration. J Biosci Bioeng 2011;112:415-21.
26. Gocheva V, Naba A, Bhutkar A, Guardia T, Miller KM, Li CM. Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival. Proc Natl Acad Sci USA 2017;114:E5625-34.
27. Moll HP, Mohrherr J, Breitenecker K, Haber M, Voronin V, Casanova E. Orthotopic transplantation of syngeneic lung adenocarcinoma cells to study PD-L1 expression. J Vis Exp 2019;2019:1-6.
28. Denisenko T V., Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma article. Cell Death Dis 2018;9:117.
29. Bagchi S, Yuan R, Engleman EG. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu Rev Pathol Mech Dis 2021;16:223-49.
30. Tripodi L, Passariello M, D’Argenio V, Leggiero E, Vitale M, Colicchio R, et al. Evaluation of the antiproliferative effect of Bifidobacterium longum BB-536 in solid tumor cell lines, co-cultured with murine splenocytes. Biochim Clin 2021;45:242-7.
31. Zhang C, Zhang C, Wang H. Immune-checkpoint inhibitor resistance in cancer treatment : Current progress and future directions. Cancer Lett 2023;562:216182.
32. Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol 2021;18:345-62
33. Dehghani T-R and PT prograz, Shahrjerdi A, Saeed M, Soleimani E, Bakhshesh M. programmed cell death protein 1 ( PD-1 ) for treatment of non-small-cell lung carcinoma ( NSCLC ); the recent advances. Pathol – Res Pract 2023;246:154470.
34. Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer 2022;21:1-27.
35. Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms Controlling PD-L1 Expression in Cancer. Mol Cell 2019;76:359-70.
36. Biegert GWG, Rosewell Shaw A, Suzuki M. Current development in adenoviral vectors for cancer immunotherapy. Mol Ther – Oncolytics 2021;23:571-81.
37. Tripodi L, Sasso E, Feola S, Coluccino L, Vitale M, Leoni G, et al. Systems Biology Approaches for the Improvement of Oncolytic Virus-Based Immunotherapies. Cancers (Basel) 2023;15:1-20.
38. Shaw AR, Suzuki M. Immunology of Adenoviral Vectors in Cancer Therapy. Mol Ther – Methods Clin Dev 2019;15:418-29.